Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Rucaparib Rubraca 250 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Mesna Mesnex 400 mg Ancillary Therapy Chemoprotective Detoxifying Agent Yes 2002 In Use
NA Regorafenib Stivarga 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET,TIE2,DDR2,TrkQ,RAF,BRAF,SAPK2, PTK, Abl Yes 2012 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Alitretinoin Panretin 0.10% Hormonal Therapy Immunomodulator Retinoic Acid Derivative No 1999 In Use
NA Avapritinib Ayvakit 300mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.3 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Ponatinib Iclusig 15 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
NA Letrozole Femara 2.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1997 In Use
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
Futibatinib Lytgobi 4mg Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.